Equities researchers at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT - Get Free Report) in a research report issued on Friday. The brokerage set a "hold" rating on the stock.
DBVT has been the topic of a number of other reports. JMP Securities restated a "market outperform" rating and set a $10.00 price objective on shares of DBV Technologies in a research report on Friday, January 10th. HC Wainwright lifted their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, October 24th.
Check Out Our Latest Report on DBVT
DBV Technologies Price Performance
NASDAQ:DBVT traded down $0.13 during trading hours on Friday, reaching $4.61. The company's stock had a trading volume of 32,925 shares, compared to its average volume of 230,293. The business's 50-day moving average is $3.38 and its 200-day moving average is $3.83. DBV Technologies has a one year low of $2.20 and a one year high of $9.49. The company has a market cap of $94.72 million, a price-to-earnings ratio of -1.02 and a beta of 0.64.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
